StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report released on Wednesday morning. The brokerage issued a hold rating on the stock.

Trinity Biotech Stock Performance

Shares of TRIB stock opened at $0.90 on Wednesday. Trinity Biotech has a 52-week low of $0.74 and a 52-week high of $3.55. The stock has a market cap of $10.06 million, a price-to-earnings ratio of -0.40 and a beta of 1.01. The firm’s 50-day moving average is $0.91 and its 200-day moving average is $1.59.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period. Institutional investors own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.